Zoetis Inc 8-K, filed Oct 25, 2022
Zoetis Inc. (ZTS)
8-K
2022-10-25
For: 2022-10-24
View Original
Added on
April 10, 2026
About this 8-K
Zoetis Inc filed this 8-K on October 25, 2022, reporting on events of October 24, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM | |||||
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 24, 2022
| (Exact name of registrant as specified in its charter) | ||
| (State or other jurisdiction | (Commission File | (I.R.S. Employer | ||||||||||||
| of incorporation) | Number) | Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(973 ) 822-7000
| (Registrant's telephone number, including area code) | ||
| Not Applicable | ||
| (Former Name or Former Address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Zoetis Inc. (the “Company”) appointed Glenn David as the Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices, effective November 1, 2022. Glenn David currently serves as Executive Vice President and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance.
As a result of these changes, the Company has appointed Jamie Brannan, who currently serves as the Company’s President, International Operations, as the Executive Vice President and Group President, International Operations and Aquaculture (PHARMAQ), effective November 1, 2022. Wafaa Mamilli, the Company’s Chief Digital and Technology Officer, will also assume oversight of China, Brazil and Precision Animal Health, effective November 1, 2022.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ZOETIS INC. | ||||||||
| Dated: October 25, 2022 | By: | /s/ Heidi C. Chen | ||||||
| Heidi C. Chen | ||||||||
| Executive Vice President, | ||||||||
| General Counsel and Corporate Secretary | ||||||||